Compare Neurocrine Biosciences Inc (NBIX) vs Wix.Com Ltd (WIX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Neurocrine Biosciences Inc vs Wix.Com Ltd — how do they compare? Neurocrine Biosciences Inc trades at $179 (market cap $17.40B), while Wix.Com Ltd trades at $53.52 (market cap $2.23B). The key difference: Neurocrine Biosciences Inc is far larger — about 7.8× Wix.Com Ltd's market cap, and Neurocrine Biosciences Inc is trading nearer its 52-week high, Wix.Com Ltd nearer its low. Which is the better fit depends on your goals.
| NBIX | WIX | |
|---|---|---|
Market Cap | $17.40B | $2.23B |
Sector | Health | Technology |
52-Week High | $180.55 | $184.24 |
52-Week Low | $123.10 | $40.43 |
Enterprise Value | $16.49B | $1.80B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Neurocrine Biosciences (NBIX) trades at $173.00, up 1.24% today, with strong technical momentum and bullish moving averages. The company demonstrates robust fundamentals with Q1 2026 EPS of $1.94 beating expectations by 59%, revenue growth to $3.1B in 2026, and net income margin expanding to 21.55%. Recent news highlights executive appointments and positive clinical trial updates for crinecerfont, supporting growth prospects.
Outlook remains positive with 86% analyst buy ratings and a $196.08 consensus price target implying 13% upside. Key risks include execution of pipeline developments and integration of acquisitions. The stock's valuation at P/E 26.62 appears reasonable given earnings growth trajectory and strong profitability metrics.
Wix.com trades at $51.12, down 0.64% on the day, with a mixed technical outlook showing bullish moving averages but overbought RSI levels. Revenue growth remains strong, reaching $1.99B in 2025, though net income margin turned negative at -1.97%. Recent news includes product launches like Wix Headless AI integration and multiple law firm investigations into potential securities fraud following a 56% stock decline in H1 2026.
The stock presents a high-risk, high-reward profile with a consensus price target of $77.50 implying 52% upside, but faces headwinds from earnings volatility, negative equity, and legal scrutiny. Long-term growth drivers in AI and small business tools are countered by near-term execution risks and competitive pressures in the website-building space.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Neurocrine Biosciences Inc
Neurocrine Biosciences, Inc. is a biopharmaceutical company focused on discovering, developing, and commercializing innovative treatments for neurological, endocrine, and psychiatric disorders. The company's portfolio targets conditions such as tardive dyskinesia, endometriosis, and Parkinson's disease. NBIX leverages its expertise in neurobiology and small-molecule drug development to address diseases with significant unmet medical needs.
Read more on NBIX →About Wix.Com Ltd
Wix.com Ltd is a cloud-based development platform provider for millions of registered users worldwide. The company is engaged in web development and management that provides an easy-to-use powerful cloud-based platform of products through a freemium model. Its core products consist of three web editors: the Wix Editor, intended for users with basic technological skills, Wix ADI, intended for novice users and Corvid, intended for more tech-savvy users. The company's web development technology is built based on HTML5 and offers HTML5 compatible capabilities, web design and layout tools, domain hosting, and other marketing and workflow management applications and services. The geographic segments include North America, Europe, Latin America, Asia and others.
Read more on WIX →
